metforminWhat was measured
Measured, with no finding
946 endpoints
Show what was measuredHide what was measured
Body mass index change
decreases
metformin use resulted in a marked decrease in body mass index [-1.24 kg/m2 (95% CI: -1.70 to -0.77)]
PMID 39509416 · one of two readings recorded this
mean weight change in kg, pooled across placebo-controlled trials
-3.32 kg (95% CI -4.57 to -2.07)
Not recorded as a finding: sentence carries a signed estimate with no direction word, and does not state the comparator contrast
The mean weight change with metformin was -3.32 kg [95% confidence interval (CI): -4.57 to -2.07].
PMID 39509416 · one of two readings recorded this
mean weight change in kg, pooled, metformin versus placebo in antipsychotic-treated patients
-3.32 kg [95% CI: -4.57 to -2.07]
Not recorded as a finding: Direction carried only as a signed estimate (-3.32 kg); body-mass node is total body mass under stated conditions and the abstract states no instrument or conditions
The mean weight change with metformin was -3.32 kg [95% confidence interval (CI): -4.57 to -2.07].
PMID 39509416 · one of two readings recorded this
Weight change
decreases
The mean weight change with metformin was -3.32 kg [95% confidence interval (CI): -4.57 to -2.07]
PMID 39509416 · one of two readings recorded this
esophageal cancer incidence (GRADE profile)
decreases, n = 12
IEC | 12 | CS | Serious | Serious | NS | Serious | No | Small | No | 0.85(0.72,0.99) | Very low
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
decreases
Chin-Hsiao Tseng, 2016, China | CS | < 21.47 | 304,229 | 16216/16216 | 25.03/50.87 | - | 8 | - | - | IEC | 0.56[0.33, 0.94]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
no effect
Claudia Becker, 2013, UK | CCS | >60 | 4,070 | 2040/2030 | - | - | 6 | - | - | IEC | 1.11[0.79, 1.54]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
decreases
Francesca Valent, 2015, Italian | CS | - | 109255 | 63119/75402 | - | - | 7 | - | - | IEC | 0.98[0.98,1.00]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
no effect
Harvey J. Murff, 2018, USA | CS | 24 | 84,434 | 42217/42217 | 50/50 | - | 6 | - | - | IEC | 0.99[0.63, 1.55]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
decreases
Joseph JY Sung, 2020, China | CS | 56.4 | 289,297 | 11,365/277,932 | - | - | 7 | - | - | IEC | 0.27[0.12, 0.59]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
no effect
Kao-Chi Cheng, 2012, China | CCS | - | 279 | 231/48 | - | - | 6 | - | - | IEC | 2.84[0.99,8.18]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
no effect
Konstantinos K. Tsilidis, 2014, UK | CS | 12 | 95,820 | 51484/18264 | - | - | 8 | - | - | IEC | 1.05[0.71, 1.56]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
no effect
Meei-Shyuan Lee, 2011, China | CS | 24 | 480,984 | 11212/4193 | 47.8/40.3 | - | 7 | - | - | IEC | 0.44[0.07, 2.61]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
decreases
Qiao-Li Wang, 2019, Sweden | CS | - | 4,527,633 | 5411,603/4116030 | 3.5 /5.3 | - | 8 | - | ESCC | IEC | 0.68[0.54, 0.85]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
decreases
Rikje Ruiter, 2012, Netherlands | CS | 12 | 85,289 | 52,698/32,591 | 30/30 | - | 7 | - | - | IEC | 0.90 [0.82, 0.97]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
no effect
Roy G. de Jong, 2017, Netherlands | CS | - | 57,114 | 37215/19899 | 376/457 | - | 8 | - | - | IEC | 0.90[0.48, 1.67]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence (per study)
no effect
Tak Kyu Oh, 2019, South Korea | CS | 9.6 | 66,627 | 29974/36653 | - | - | 7 | - | - | IEC | 0.38 [0.13, 1.13]
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.04
The random effects model showed that compared with the control groups, metformin might decrease EC incidence (OR = 0.87, P = 0.04)
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
no effect, p = 0.88, n = 2
BMI | >30 | 2 | 0.85 | 0% | Fixed | 1.02 [0.76, 1.38] | 0.88
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
no effect, p = 0.07, n = 9
Non-metformin | 9 | <0.0001 | 76% | Random | 0.78 [0.59, 1.02] | 0.07
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.02, n = 3
Comparators | Sulfonylureas | 3 | 0. 7 | 0% | Fixed | 0.91 [0.84, 0.99] | 0.02
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.03
60≥ | 7& | 0.18 | 33% | Fixed | 0.92 [0.85, 0.99] | 0.03
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.0001, n = 3
Mean age | <60 | 3 | 0.72 | 0% | Fixed | 0.66 [0.53, 0.81] | <0.0001
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.0001, n = 4
Region | Asia | 4 * | 0.52 | 0% | Fixed | 0.44 [0.29, 0.65] | <0.0001
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.0004
Europe and America | 6# | 0.42 | 0% | Fixed | 0.98 [0.97, 0.99] | 0.0004
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.0001, n = 3
Sample size | ≥300000 | 3 | 0.72 | 0% | Fixed | 0.66 [0.53, 0.81] | <0.0001
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.0004
<300000 | 8& | 0.11 | 41% | Fixed | 0.98 [0.97, 0.99] | 0.0004
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
no effect, p = 0.6, n = 3
adjusted | 3 | 0.92 | 0% | Fixed | 1.06 [0.85, 1.32] | 0.6
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
no effect, p = 0.6, n = 3
Adjusted | 3# | 0.92 | 0% | Fixed | 1.06 [0.85, 1.32] | 0.6
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.01, n = 9
BMI | No adjusted | 9 | <0.0001 | 78% | Random | 0.81 [0.69, 0.95] | 0.01
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
no effect, p = 0.07, n = 8
Smoking | No adjusted | 8 | 0.0004 | 74% | Random | 0.86 [0.73, 1.01] | 0.07
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases
No | 6& | 0.11 | 44% | Fixed | 0.81 [0.68, 0.95] | 001
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
no effect, p = 0.33, n = 5
Time-related biases | Yes | 5 | 0.01 | 69% | Random | 0.94 [0.84, 1.06] | 0.33
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.004, n = 4
Use of aspirin | Yes | 4 | 0.14 | 45% | Fixed | 0.76 [0.63, 0.91] | 0.004
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
no effect, p = 0.09, n = 2
Use of Insulin | Yes | 2 | 0.4 | 0% | Fixed | 0.49 [0.21, 1.11] | 0.09
PMID 39774829 · one of two readings recorded this
esophageal cancer incidence
decreases, p = 0.006, n = 3
Use of statins | Yes | 3 | 0.15 | 47% | Fixed | 0.77 [0.64, 0.93] | 0.006
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer (GRADE profile)
decreases, n = 5
OS | 5 | CS | Serious | NS | NS | NS | No | Small | No | 0.87(0.80,0.95) | Low
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer patients with diabetes, pooled hazard ratio
increases, HR 0.87, p = 0.002
Not recorded as a finding: no outcome node for overall survival in a cancer population; progression-free-survival and patient-survival-rate nodes do not match a pooled HR for OS
The results showed that metformin could increase the OS of EC patients with diabetes (HR 0.87, P = 0.002), as shown in Fig 4.
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer (per study)
decreases
Huang-He He, 2020, China | CS | - | 619 | 485/134 | - | 69.07%/77.61% | 8 | II-III (77.7%) | ESCC (100%) | OS | 0.89 [0.80, 0.99]
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer (per study)
no effect
L. E. A. M. M. Spierings, 2015, Netherlands | CS | - | 43 | 32/11 | - | 6 | T3(77.7%) N1-N2(71.1%) | Adenocarcinoma (68.3%) | OS | 0.49 [0.08, 2.92]
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer (per study)
decreases
L. Van De Voorde, 2015, Netherlands | CS | - | 196 | 19/177 | - | 21%/50.3% | 6 | T3 (68%) N0-N1 (80%) | Adenocarcinoma (78.1%) | OS | 0.35 [0.13, 0.97]
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer (per study)
no effect
Qiaoli Wang, 2023, Sweden | CS | 12 | 852 | 473/379 | - | 79.9%/90.7% | 8 | III-IV (59.3%) | Adenocarcinoma (57.6%) ESCC (37.0%) | OS | 0.86[0.75,1.00]
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.002
The results showed that metformin could increase the OS of EC patients with diabetes (HR 0.87, P = 0.002)
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.02, n = 3
≤70 | 3 | 0.17 | 44% | Fixed | 0.88 [0.79, 0.98] | 0.02
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
no effect, p = 0.09, n = 1
Age | >70 | 1 | - | - | - | 0.84 [0.69, 1.03] | 0.09
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.02, n = 3
BMI | <30 | 3 | 0.11 | 44% | Fixed | 0.88 [0.79, 0.98] | 0.02
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
no effect, p = 0.07, n = 3
Histology | Adenocarcinoma | 3 | 0.18 | 42% | Fixed | 0.85 [0.72, 1.01] | 0.07
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.02, n = 2
Squamous cell carcinoma | 2 | 0.77 | 0% | Fixed | 0.89 [0.80, 0.98] | 0.02
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.03, n = 1
Asia | 1 | - | - | - | 0.89 [0.80, 0.99] | 0.03
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.02, n = 3
Region | Europe and America | 3 | 0.19 | 39% | Fixed | 0.84 [0.73, 0.97] | 0.02
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.003, n = 2
≥500 | 2 | 0.71 | 0% | Fixed | 0.88 [0.81, 0.96] | 0.003
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.003, n = 2
Sample size | <500 | 2 | 0.75 | 0% | Fixed | 0.38 [0.16, 0.92] | 0.003
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.01, n = 2
Predominantly Female | 2 | 0.59 | 0% | Fixed | 0.88 [0.80, 0.98] | 0.01
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
no effect, p = 0.05, n = 3
Sex | Predominantly male | 3 | 0.19 | 40% | Fixed | 0.85 [0.72, 1.00] | 0.05
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.03, n = 1
adjusted | 1 | - | - | - | 0.89 [0.80, 0.99] | 0.03
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.02, n = 3
BMI | No adjusted | 3 | 0.19 | 39% | Fixed | 0.84 [0.73, 0.97] | 0.02
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.02, n = 3
Smoking | No adjusted | 3 | 0.19 | 39% | Fixed | 0.84 [0.73, 0.97] | 0.02
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.03, n = 2
Surgery + NC | Yes | 2 | 0.75 | 0% | Fixed | 0.38 [0.16, 0.92] | 0.03
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.02, n = 4
Surgery | Yes | 4 | 0.25 | 26% | Fixed | 0.89 [0.80, 0.98] | 0.02
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
decreases, p = 0.03, n = 2
Use of statins | Yes | 2 | 0.54 | 0% | Fixed | 0.86 [0.74, 0.99] | 0.03
PMID 39774829 · one of two readings recorded this
overall survival in esophageal cancer
no effect, p = 0.08, n = 1
Without Surgery | Yes | 1 | - | - | - | 0.87 [0.75, 1.01] | 0.08
PMID 39774829 · one of two readings recorded this
overall survival (OS) of esophageal cancer patients with diabetes, pooled hazard ratio
HR 0.87, p = 0.002
Not recorded as a finding: no_outcome_node: overall survival as a pooled time-to-event hazard ratio has no entry in the outcome list (patient-survival-rate is a proportion alive at a stated follow-up)
The results showed that metformin could increase the OS of EC patients with diabetes (HR 0.87, P = 0.002), as shown in Fig 4.
PMID 39774829 · one of two readings recorded this
death after stroke (survival status, longest follow-up), pooled OR, prestroke metformin use versus none in diabetic patients; also poor functional course (mRS 3-6) pooled OR 0.66
decreases, OR=0.57, 95% CI: 0.51 to 0.64
Not recorded as a finding: the supporting sentence never names the compound
Individual ORs ranged from 0.16 (95% CI: 0.02 to 1.33) to 0.73 (95% CI: 0.47 to 1.13), and the pooled analysis indicated a 43% reduction in the probability of death after stroke (OR=0.57, 95% CI: 0.51 to 0.64, p<0.001).
PMID 39819905 · one of two readings recorded this
Death after stroke (survival status)
decreases, p = 0.001, n = 15908
the pooled analysis indicated a 43% reduction in the probability of death after stroke (OR=0.57, 95% CI: 0.51 to 0.64, p<0.001)
PMID 39819905 · one of two readings recorded this
Egger's test publication bias, functional outcome
no effect, p = 0.503
effect of metformin use on functional outcome (p=0.503)
PMID 39819905 · one of two readings recorded this
Egger's test publication bias, survival status
no effect, p = 0.608
functional outcome (p=0.503) and survival status (p=0.608)
PMID 39819905 · one of two readings recorded this
poor functional course after stroke (modified Rankin Scale 3-6), longest follow-up
decreases, OR=0.66, 95% CI: 0.61 to 0.72
Not recorded as a finding: mrs-0-2-90-days requires the 0-2 cut at 90 days; this pooled estimate is poor course (3-6) at the longest follow-up each study reported
Individual ORs ranged from 0.49 (95% CI: 0.24 to 0.97) to 0.87 (95% CI: 0.72 to 1.05), and pooled analysis showed that prestroke metformin use could reduce the probability of poor course after stroke by 34% in DM patients (OR=0.66, 95% CI: 0.61 to 0.72, p<0.001).
PMID 39819905 · one of two readings recorded this
Poor functional outcome after stroke (mRS 3-6)
decreases, p = 0.001
pooled analysis showed that prestroke metformin use could reduce the probability of poor course after stroke by 34% in DM patients (OR=0.66, 95% CI: 0.61 to 0.72, p<0.001)
PMID 39819905 · one of two readings recorded this
fasting plasma glucose reduction SUCRA
300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction SUCRA
300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction SUCRA
300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction SUCRA
300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction SUCRA
300 mg of canagliflozin (90%) was the best option for FPG reduction, followed by 10 mg of ertugliflozin (86%), 10 mg of henagliflozin (84%), 15 mg of ertugliflozin (82%) and 25 mg of ertugliflozin (80%)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
decreases
300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
decreases
300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
no effect
1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
decreases
300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
decreases
300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
decreases
300 mg and 200 mg of canagliflozin, 10 mg and 25 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −2.02 (−2.50, −1.50), −1.83 (−2.63, −1.04), −1.96 (−2.69, −1.23), −1.84 (−2.57, −1.11), −1.89 (−2.54, −1.23), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
no effect
1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
no effect
1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
no effect
1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)
PMID 40010842 · one of two readings recorded this
fasting plasma glucose reduction
no effect
1 mg of empagliflozin, 12.5 mg of ipragliflozin, and 2.5 mg, 5 mg and 10 mg of luseogliflozin (MD (95% CI), −0.23 (−0.89, 0.44), −0.61 (−1.32, 0.12), −0.38 (−1.11, 0.34), −0.63 (−1.35, 0.09), −0.67 (−1.39, 0.05), respectively)
PMID 40010842 · one of two readings recorded this
genital infections
increases
only 10 mg of empagliflozin increased the incidence of GI (OR (95% CI), 12.73 (1.37, 437.17))
PMID 40010842 · one of two readings recorded this
HbA1c reduction SUCRA
15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)
PMID 40010842 · one of two readings recorded this
HbA1c reduction SUCRA
15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)
PMID 40010842 · one of two readings recorded this
HbA1c reduction SUCRA
15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)
PMID 40010842 · one of two readings recorded this
HbA1c reduction SUCRA
15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)
PMID 40010842 · one of two readings recorded this
HbA1c reduction SUCRA
15 mg of ertugliflozin (81%) ranked the highest in reducing HbA1c, followed by 10 mg of henagliflozin (80%), 300 mg of canagliflozin (77%), 5 mg of ertugliflozin (76%) and 5 mg of henagliflozin (76%)
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively
PMID 40010842 · one of two readings recorded this
HbA1c reduction
no effect
2.5 mg of dapagliflozin and 1 mg and 5 mg of empagliflozin (MD (95% CI), −0.37 (−0.78, 0.05), −0.16 (−0.58, 0.26) and −0.30 (−0.72, 0.12), respectively)
PMID 40010842 · one of two readings recorded this
HbA1c reduction
no effect
2.5 mg of dapagliflozin and 1 mg and 5 mg of empagliflozin (MD (95% CI), −0.37 (−0.78, 0.05), −0.16 (−0.58, 0.26) and −0.30 (−0.72, 0.12), respectively)
PMID 40010842 · one of two readings recorded this
HbA1c reduction
no effect
2.5 mg of dapagliflozin and 1 mg and 5 mg of empagliflozin (MD (95% CI), −0.37 (−0.78, 0.05), −0.16 (−0.58, 0.26) and −0.30 (−0.72, 0.12), respectively)
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
10 mg and 5 mg of henagliflozin, 15 mg and 25 mg of ertugliflozin, and 300 mg of canagliflozin showed reductions of −0.80% (−1.26, −0.34), −0.76% (−1.22, −0.30), −0.78% (−1.10, −0.46), −0.74% (−1.22, −0.27) and −0.74% (−1.07, −0.40), respectively
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
300 mg of canagliflozin, 5 mg and 15 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −0.58% (−1.12, −0.04), −0.57% (−1.08, −0.06), −0.62% (−1.15, −0.09) and −0.64% (−1.27, −0.02), respectively)
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
300 mg of canagliflozin, 5 mg and 15 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −0.58% (−1.12, −0.04), −0.57% (−1.08, −0.06), −0.62% (−1.15, −0.09) and −0.64% (−1.27, −0.02), respectively)
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
300 mg of canagliflozin, 5 mg and 15 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −0.58% (−1.12, −0.04), −0.57% (−1.08, −0.06), −0.62% (−1.15, −0.09) and −0.64% (−1.27, −0.02), respectively)
PMID 40010842 · one of two readings recorded this
HbA1c reduction
decreases
300 mg of canagliflozin, 5 mg and 15 mg of ertugliflozin, and 10 mg of henagliflozin (MD (95% CI), −0.58% (−1.12, −0.04), −0.57% (−1.08, −0.06), −0.62% (−1.15, −0.09) and −0.64% (−1.27, −0.02), respectively)
PMID 40010842 · one of two readings recorded this
hypoglycaemia incidence
increases
5 mg and 50 mg of empagliflozin, 5 mg and 15 mg of ertugliflozin, and 25 mg of janagliflozin exhibited higher incidence of hypoglycaemia (OR (95% CI), 6.00×106 (16.54, 7.12×1015), 1.36×106 (2.35, 1.55×1015), 2.29 (1.02, 6.18), 2.56 (1.09, 7.18), 2.50×106 (6.38, 1.88×1022) respectively)
PMID 40010842 · one of two readings recorded this
hypoglycaemia incidence
increases
5 mg and 50 mg of empagliflozin, 5 mg and 15 mg of ertugliflozin, and 25 mg of janagliflozin exhibited higher incidence of hypoglycaemia (OR (95% CI), 6.00×106 (16.54, 7.12×1015), 1.36×106 (2.35, 1.55×1015), 2.29 (1.02, 6.18), 2.56 (1.09, 7.18), 2.50×106 (6.38, 1.88×1022) respectively)
PMID 40010842 · one of two readings recorded this
total adverse events
increases
10 mg of henagliflozin was associated with increased AEs (OR (95% CI), 2.29 (1.29, 4.14))
PMID 40010842 · one of two readings recorded this
weight loss SUCRA
300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)
PMID 40010842 · one of two readings recorded this
weight loss SUCRA
300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)
PMID 40010842 · one of two readings recorded this
weight loss SUCRA
300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)
PMID 40010842 · one of two readings recorded this
weight loss SUCRA
300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)
PMID 40010842 · one of two readings recorded this
weight loss SUCRA
300 mg of canagliflozin (97%) demonstrated best efficacy in WL, followed by 20 mg of bexagliflozin (85%), 10 mg of ertugliflozin (80%), 100 mg of canagliflozin (79%) and 0.3 mg of enavogliflozin (77%)
PMID 40010842 · one of two readings recorded this
weight loss
no effect
1 mg of empagliflozin and 12.5 mg of ipragliflozin (MD (95% CI), −0.57 (−1.38, 0.23), −0.40 (−1.27, 0.48), respectively)
PMID 40010842 · one of two readings recorded this
weight loss
no effect
1 mg of empagliflozin and 12.5 mg of ipragliflozin (MD (95% CI), −0.57 (−1.38, 0.23), −0.40 (−1.27, 0.48), respectively)
PMID 40010842 · one of two readings recorded this
class 3 obesity prevalence
Almost all patients prescribed metformin were overweight or obese (94.8%), and prescription rates were highest in those with class 3 obesity (46.5%)
PMID 40274755 · one of two readings recorded this
class 3 obesity prevalence
Among patients who did not receive a metformin prescription order, the overall proportion with overweight/obesity and those with class 3 obesity was comparatively smaller (87.7% and 29.6%, respectively)
PMID 40274755 · one of two readings recorded this
diabetes incidence
n = 59232
A total of 5,314 (9.0%) of patients developed diabetes (identified by diagnosis code or two glycemic tests) during the 5-year study period
PMID 40274755 · one of two readings recorded this
diabetes progression timing
< 1 year | 1,955 (32.6)
PMID 40274755 · one of two readings recorded this
diabetes progression timing
1–3 years | 2,420 (40.4)
PMID 40274755 · one of two readings recorded this
diabetes progression timing
3–5 years | 939 (15.7)
PMID 40274755 · one of two readings recorded this
diabetes progression timing
5 + years | 683 (11.4)
PMID 40274755 · one of two readings recorded this
metformin prescription association with ethnicity
p = 0.28
The bivariate association of patient characteristics with metformin prescription status was significant for every variable except ethnicity (p = 0.28)
PMID 40274755 · one of two readings recorded this
metformin prescription
n = 57014
Total | 57,014 | 1,699 (3.0) | 53,666 | 3,259 (6.1)
PMID 40274755 · one of two readings recorded this
metformin prescription
n = 53666
Total | 57,014 | 1,699 (3.0) | 53,666 | 3,259 (6.1)
PMID 40274755 · one of two readings recorded this
metformin prescription
18–29 Years | 1.08 (0.94–1.24)
PMID 40274755 · one of two readings recorded this
metformin prescription
30–39 Years | 0.94 (0.83–1.06)
PMID 40274755 · one of two readings recorded this
metformin prescription
40–49 Years | 0.88 (0.79–0.99)
PMID 40274755 · one of two readings recorded this
metformin prescription
50–59 Years | 1.04 (0.92–1.16)
PMID 40274755 · one of two readings recorded this
metformin prescription
n = 14980
Age < 60 years & Class 2 or 3 obese | 14,980 | 682 (4.5) | 13,974 | 1,320 (9.4)
PMID 40274755 · one of two readings recorded this
metformin prescription
n = 13974
Age < 60 years & Class 2 or 3 obese | 14,980 | 682 (4.5) | 13,974 | 1,320 (9.4)
PMID 40274755 · one of two readings recorded this
metformin prescription
n = 47797
Age < 60 years | 47,797 | 1,368 (2.9) | 43,048 | 2,643 (6.1)
PMID 40274755 · one of two readings recorded this
metformin prescription
n = 43048
Age < 60 years | 47,797 | 1,368 (2.9) | 43,048 | 2,643 (6.1)
PMID 40274755 · one of two readings recorded this
metformin prescription
n = 17484
Class 2 or 3 obese | 17,484 | 770 (4.4) | 16,210 | 1,495 (9.2)
PMID 40274755 · one of two readings recorded this
metformin prescription
n = 16210
Class 2 or 3 obese | 17,484 | 770 (4.4) | 16,210 | 1,495 (9.2)
PMID 40274755 · one of two readings recorded this
metformin prescription
Hispanic | 1.00 (0.90–1.11)
PMID 40274755 · one of two readings recorded this
metformin prescription
Unknown | 0.95 (0.75–1.19)
PMID 40274755 · one of two readings recorded this
metformin prescription
ICD code | 0.84 (0.74–0.95)**
PMID 40274755 · one of two readings recorded this
metformin prescription
Medicare | 1.12 (0.95–1.32)
PMID 40274755 · one of two readings recorded this
metformin prescription
Private | 1.11 (0.98–1.25)
PMID 40274755 · one of two readings recorded this
metformin prescription
Uninsured | 1.05 (0.95–1.17)
PMID 40274755 · one of two readings recorded this
metformin prescription
Unknown | 0.73 (0.65–0.82)**
PMID 40274755 · one of two readings recorded this
metformin prescription
Another | 0.49 (0.35–0.68)**
PMID 40274755 · one of two readings recorded this
metformin prescription
Asian | 0.65 (0.52–0.80)**
PMID 40274755 · one of two readings recorded this
metformin prescription
Black | 0.76 (0.69–0.85)**
PMID 40274755 · one of two readings recorded this
metformin prescription
Unknown | 0.54 (0.48–0.61)**
PMID 40274755 · one of two readings recorded this
metformin prescription
Female | 1.09 (1.00–1.18)*
PMID 40274755 · one of two readings recorded this
metformin prescription
Class 1 obese | 2.29 (1.93–2.72)**
PMID 40274755 · one of two readings recorded this
metformin prescription
Class 2 or 3 obese | 3.75 (3.18–4.44)**
PMID 40274755 · one of two readings recorded this
metformin prescription
greater multivariable odds of metformin prescription were observed among those with overweight (OR:1.66 [CI: 1.39–1.98])
PMID 40274755 · one of two readings recorded this
metformin prescription
Underweight | 0.65 (0.26–1.59)
PMID 40274755 · one of two readings recorded this
overweight or obesity prevalence
Almost all patients prescribed metformin were overweight or obese (94.8%), and prescription rates were highest in those with class 3 obesity (46.5%)
PMID 40274755 · one of two readings recorded this
overweight or obesity prevalence
Among patients who did not receive a metformin prescription order, the overall proportion with overweight/obesity and those with class 3 obesity was comparatively smaller (87.7% and 29.6%, respectively)
PMID 40274755 · one of two readings recorded this
receipt of a metformin prescription order within 1 and 5 years of prediabetes diagnosis, by patient BMI, race, sex and insurance status
Not recorded as a finding: the compound is what was measured, not what was given
Overall, 3.0% and 6.1% of FQHC patients with prediabetes received a metformin prescription within one and five years of their prediabetes identification, respectively (Table 3).
PMID 40274755 · one of two readings recorded this
White race proportion
White patients constituted 49.8% of the sample and accounted for 57.3% of patients who received a metformin prescription
PMID 40274755 · one of two readings recorded this
All-cause mortality
decreases, p = 0.001, n = 733873
The pooled RR was 0.79 (95% CI: 0.71–0.88; p<0.001)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Bazo-Alvarez JC | 2021 | Type 2 diabetes patients in second antidiabetic drug | 3.5 | MACE, Death | 0.94(0.81-1.10) | 0.97(0.81-1.16)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Cho YY | 2018 | All patients with T2Dwho initiated second-line treatment | 5.2 | Death | – | 0.59(0.36-0.98)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Eriksson JW | 2016 | All patients with T2D in Sweden who initiated second-line treatment | 3 | Death | – | 0.70(0.56-0.87)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Franchi M | 2024 | Type 2 diabetes patients who received DPP-4is or SUs in addition to metformin | 5.61 | MACE, Death | 0.78 (0.63-0.97) | 0.73 (0.55- 0.98)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Gallwitz B | 2012 | Type 2 diabetes inadequately controlled on metformin | 2 | MACE, Death | 0.49(0.23-1.01) | 1.00 (0.14–7.07)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Ha KH | 2017 | Patients with DM-2 treated with metformin and an additional anti-diabetic agent. | 2.3 | Death | – | 0.84(0.66-1.07)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Her AY | 2024 | Type 2 diabetes patients with diabetes and acute myocardial infarction | 3 | MACE, Death | 0.48(0.12-1.90) | 0.72(0.41-1.27)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Hippisley-Cox J [51] | 2016 | Type 2 diabetes patients in second antidiabetic drug | 3 | Death | – | 0.62(0.55-0.71)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Hsu PF | 2018 | Type 2 diabetes inadequately controlled on metformin | 11 | MACE, Death | 0.78(0.69-0.88) | 0.956 (0.847–1.078)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Kannan S | 2016 | Patients with DM-2 treated with metformin and an additional anti-diabetic agent. | 4 | Death | – | 1.029 (0.81 - 1.31)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Kim KJ | 2019 | Type 2 diabetes patients in second antidiabetic drug | 1.63 | MACE, Death | 0.67(0.33-1.36) | 0.74(0.46-1.18)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Mogensen UM | 2014 | Type 2 diabetes inadequately controlled on metformin | 2.3 | MACE, Death | 0.57(0.40-0.80) | 0.57(0.40-0.80)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Morgan CL | 2014 | Type 2 diabetes were selected if initiated with combination therapies comprising metformin plus SUs or DPP-4is | 1.8 | MACE, Death | 0.64(0.45-0.93) | 0.67(0.49-0.91)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Ou HT | 2017 | All patients with T2Dwho initiated second-line treatment | 3.3 | MACE, Death | 0.82(0.69-0.97) | 0.82(0.69-0.99)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Ou SM | 2015 | All patients with Type 2 diabetes aged 20 years or older | 2.5 | MACE, Death | 0.67(0.59-0.78) | 0.63(0.55-0.72)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Thein D | 2020 | Type 2 diabetes patients in second antidiabetic drug | 2 | MACE, Death | 0.82(0.67-0.97) | 0.88(0.76-1.01)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Vaccaro O | 2017 | All patients with T2DM aged 50–75 years | 2 | MACE, Death | 0.83(0.54-1.29) | 1.10 (0·75–1·61)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect
Wang H | 2023 | Type 2 diabetes patients who received DPP-4is or SUs in addition to metformin | 2.7 | MACE, Death | 1.02(0.92-1.13) | 0.99(0.89-1.09)
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases
Yu OH | 2015 | Type 2 diabetes inadequately controlled on metformin | 2 | Death | – | 0.53(0.29-0.97)
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect, p = 0.088
Age average | <60 | 5 | 0.83(0.68-1.03) | 0.088
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.021
Follow up time | ≤2 years | 6 | 0.81(0.68-0.97) | 0.021
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.029
Quality assessment | Good quality | 7 | 0.78(0.62-0.97) | 0.029
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.001
Moderate quality | 12 | 0.80(0.70-0.90) | ≤0.001
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.003
Sample size | <3000 | 13 | 0.81(0.71-0.93) | 0.003
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.001
Case- control | 1 | 0.57(0.40-0.81) | 0.001
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.001
Cohort | 16 | 0.79(0.71-0.88) | ≤0.001
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect, p = 0.631
Study design | RCT | 2 | 1.10(0.79-1.59) | 0.631
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect, p = 0.81
Study location | America and Canada | 1 | 1.03(0.81-1.31) | 0.810
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.007
Asia | 6 | 0.76(0.62-0.93) | 0.007
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.001
Europe | 11 | 0.78(0.68-0.90) | 0.001
PMID 40323973 · one of two readings recorded this
All-cause mortality
no effect, p = 1
International | 1 | 1(0.14-7.11) | 1.000
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.001
Time period | 2017 or earlier | 8 | 0.68(0.59-0.78) | ≤0.001
PMID 40323973 · one of two readings recorded this
All-cause mortality
decreases, p = 0.004
2018 or later | 11 | 0.90(0.84-0.97) | 0.004
PMID 40323973 · one of two readings recorded this
MACE publication bias Begg's test
no effect, p = 0.216
Assessment for publication bias using Begg’s test (p = 0.216) and Egger’s test (p = 0.865)
PMID 40323973 · one of two readings recorded this
MACE publication bias Egger's test
no effect, p = 0.865
Assessment for publication bias using Begg’s test (p = 0.216) and Egger’s test (p = 0.865)
PMID 40323973 · one of two readings recorded this
MACE
no effect
Bazo-Alvarez JC | 2021 | Type 2 diabetes patients in second antidiabetic drug | 3.5 | MACE, Death | 0.94(0.81-1.10) | 0.97(0.81-1.16)
PMID 40323973 · one of two readings recorded this
MACE
no effect
Chang YC | 2015 | Type 2 diabetes inadequately controlled on metformin | 0.74 | MACE | 0.90(0.74-1.04) | –
PMID 40323973 · one of two readings recorded this
MACE
decreases
Franchi M | 2024 | Type 2 diabetes patients who received DPP-4is or SUs in addition to metformin | 5.61 | MACE, Death | 0.78 (0.63-0.97) | 0.73 (0.55- 0.98)
PMID 40323973 · one of two readings recorded this
MACE
no effect
Gallwitz B | 2012 | Type 2 diabetes inadequately controlled on metformin | 2 | MACE, Death | 0.49(0.23-1.01) | 1.00 (0.14–7.07)
PMID 40323973 · one of two readings recorded this
MACE
no effect
Gitt AK | 2013 | Patients with type 2 diabetes in which antidiabetic therapy was intensified | 1 | MACE | 1.26(0.44-3.56) | –
PMID 40323973 · one of two readings recorded this
MACE
no effect
Her AY | 2024 | Type 2 diabetes patients with diabetes and acute myocardial infarction | 3 | MACE, Death | 0.48(0.12-1.90) | 0.72(0.41-1.27)
PMID 40323973 · one of two readings recorded this
MACE
decreases
Hsu PF | 2018 | Type 2 diabetes inadequately controlled on metformin | 11 | MACE, Death | 0.78(0.69-0.88) | 0.956 (0.847–1.078)
PMID 40323973 · one of two readings recorded this
MACE
no effect
Kim KJ | 2019 | Type 2 diabetes patients in second antidiabetic drug | 1.63 | MACE, Death | 0.67(0.33-1.36) | 0.74(0.46-1.18)
PMID 40323973 · one of two readings recorded this
MACE
decreases
Mogensen UM | 2014 | Type 2 diabetes inadequately controlled on metformin | 2.3 | MACE, Death | 0.57(0.40-0.80) | 0.57(0.40-0.80)
PMID 40323973 · one of two readings recorded this
MACE
decreases
Morgan CL | 2014 | Type 2 diabetes were selected if initiated with combination therapies comprising metformin plus SUs or DPP-4is | 1.8 | MACE, Death | 0.64(0.45-0.93) | 0.67(0.49-0.91)
PMID 40323973 · one of two readings recorded this
MACE
decreases
O’Brien MJ | 2018 | All patients with T2Dwho initiated second-line treatment | 1.3 | MACE | 0.78(0.66-0.93) | –
PMID 40323973 · one of two readings recorded this
MACE
decreases
Ou HT | 2017 | All patients with T2Dwho initiated second-line treatment | 3.3 | MACE, Death | 0.82(0.69-0.97) | 0.82(0.69-0.99)
PMID 40323973 · one of two readings recorded this
MACE
decreases
Ou SM | 2015 | All patients with Type 2 diabetes aged 20 years or older | 2.5 | MACE, Death | 0.67(0.59-0.78) | 0.63(0.55-0.72)
PMID 40323973 · one of two readings recorded this